| Literature DB >> 29260041 |
T A Sumonu1, F Imarhiagbe2, L F Owolabi3, O A Ogunrin2, M A Komolafe4, O S Ilesanmi5.
Abstract
INTRODUCTION: Neurocognitive dysfunction is a detrimental complication of HIV infection. In this study we attempt to characterize the pattern of cognitive dysfunction in a sample of Nigerian patients with newly diagnosed HIV infection.Entities:
Keywords: Cognitive functions; Dementia; Human immunodeficiency virus infection; Nigeria
Year: 2017 PMID: 29260041 PMCID: PMC5731538 DOI: 10.1016/j.ensci.2017.10.001
Source DB: PubMed Journal: eNeurologicalSci ISSN: 2405-6502
Socio-demographic characteristics of study participants.
| Variables | Cases | Control | Statistics | P |
|---|---|---|---|---|
| Sex | ||||
| Male | 31(62.0) | 32(64.0) | X2 = 0.043 | 0.5000 |
| Female | ||||
| Mean age (Year) | 19(38.0) | 18(36.0) | ||
| Level of education | 36.44 ± 8.22 | 35.40 ± 11.53 | t = 0.519 | 0.605 |
| Completed | ||||
| (Primary) | 7(14.0) | 2(4.0) | X2 = 3.420 | 0.180 |
| Secondary | 26(52.0) | 32(64.0) | ||
| Tertiary | 17(34.0) | 16(32.0) |
Primary: At least 1–6 years of education.
Secondary: 7–12 years of education.
Tertiary: > 12 years of education.
p ≤ 0.05: Significant.
χ2: Chi-square value.
t: Student t-test value.
Frequency distribution of clinical/laboratory variables in patients with HIV infection.
| Variable | N | % | |
|---|---|---|---|
| 1. | PCV (%) | ||
| 20–29 | 25 | (52.1) | |
| ≥ 30 | 23 | (47.9) | |
| 2. | CD4 cell count (cell/l) | ||
| ≤ 200 | 33 | (66.0) | |
| 200–499 | 15 | (30.0) | |
| ≥ 500 | 2 | (4.0) | |
| 3. | Presence of opportunistic infections | ||
| PTB | 12 | (24.0) | |
| Oral cand | 3 | (6.0) | |
| PTB + oral cand | 4 | (8.0) | |
| PTB = skin herpes | 1 | (2.0) | |
| CNS toxoplasmosis | 2 | (4.0) | |
| None | 28 | (56.0) | |
| 4. | WHO Stage | ||
| 1 | 5 | (10.2) | |
| 2 | 9 | (18.4) | |
| 3 | 30 | (61.2) | |
| 4 | 5 | (10.2) | |
| 5. | Weight (kg) | ||
| 30–39 | 5 | (10.9) | |
| 40–49 | 12 | (26.1) | |
| 50–59 | 21 | (45.7) | |
| 60–69 | 6 | (13.0) | |
| ≥ 70 | 2 | (4.3) | |
N = Number of Patients.
Oral cand = Oral candidiasis.
Study participants with severe neurocognitive impairment and minor neurocognitive disorder.
| Participants | Cases | Controls | X2 | P |
|---|---|---|---|---|
| Participants with Total CSID Score below 2SD | 11 | 0 | 12.350 | ≤ 0.001 |
| Participants with Total CSID above 2SD | 39 | 50 | ||
| Participants with Total CSID Score between 2SD and 1SD | 23 | 18 | 4.655 | 0.03 |
| Participants with Total CSID Score above 1SD | 16 | 32 | ||
SD = Standard Deviation.
Severe neurocognitive impairment = Participants with total CSID score less than 2SD of the mean of the control.
Minor neurocognitive disorder = Subject with total CSID score that were between two 2SD and 1SD of the control mean value.
x2 – Chi square test value.
p – Level of significance.
p < 0.05 = Significant.
Comparison of cognitive performances between patients with HIV infection and Controls using CSID.
| Cognitive | Cases (N = 50) | Controls (N = 50) | p |
|---|---|---|---|
| Functions subtest | Mean ± SD | Mean ± SD | |
| Comprehension | 7.59 ± 3.25 | 10.42 ± 3.97 | ≤ 0.001 |
| Language | 26.86 ± 4.85 | 32.40 ± 4.6 | ≤ 0.001 |
| Orientation | 11.42 ± 1.61 | 11.96 ± 0.20 | 0.020 |
| Attention | 7.60 ± 0.97 | 7.60 ± 0.20 | ≤ 0.001 |
| Praxis | 1.08 ± 0.57 | 1.66 ± 0.48 | ≤ 0.001 |
| CSID Total | 66.32 ± 9.01 | 76.34 ± 6.50 | ≤ 0.001 |
SD – Standard deviation.
p- ≤ 0.3 – small effect sizes.
≤ 0.5–0.7 medium effect sizes.
≤ 0.8 – large effect sizes.
Relationship between clinical variables and cognitive functions in patients with HIV infection.
| Variables | N | Language | (Mean) | Orientation | Attention | Praxis | Total CISD | |
|---|---|---|---|---|---|---|---|---|
| Compr. | Expression | Mean | Mean | Mean | Mean | |||
| 1. | Presence of opportunistic infections | |||||||
| Yes | 22 | 4.86 | 25.50 | 10.91 | 7.45 | 1.05 | 63.32 | |
| No | 28 | 5.00 | 27.93 | 11.82 | 7.71 | 1.11 | 68.68 | |
| p | 0.13 | 0.08 | 0.04 | 0.35 | 0.71 | 0.04 | ||
| 2. | Types of Opportunistic Infections | |||||||
| PTB | 12 | 5.00 | 26.33 | 11.50 | 7.75 | 0.92 | 65.58 | |
| Oral cand. | 3 | 5.00 | 25.33 | 12.00 | 8.00 | 1.33 | 68.67 | |
| PTD + Oral cand. | 4 | 4.75 | 28.50 | 11.50 | 7.75 | 1.25 | 67.25 | |
| PTD + Herpes simplex | 1 | 5.00 | 24.00 | 8.00 | 6.00 | 1.00 | 55.00 | |
| CNS Toxo. | 2 | 4.00 | 15.50 | 6.00 | 5.00 | 1.00 | 38.00 | |
| p | 0.60 | 0.02 | ≤ 0.01 | ≤ 0.01 | 0.80 | ≤ 0.01 | ||